Who We Are
Mission & Vision
Management
Who We Are


Hebei Senlangbio Biotechnology Co. Ltd. ("SenlangBio") is a clinical-stage biotechnology company dedicated to utilize cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.


Our three cell therapy technology platforms include chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR Gamma Delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs).   


SenlangBio is currently the largest cell therapy company in Northern China in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs.   We are in the process of further capturing the cell therapy markets in other regions of China, as well as planning for international multi-center clinical studies.



ABUIABACGAAggKb0gwYo9IuMowMw2wU4jAQ
Mission & Vision


Develop and Deliver

Next Generation Cellular Immunotherapies


ABUIABACGAAg6s-0gwYo14z6oAYw4QY47gM
Management
ABUIABACGAAgzqX0gwYomKr9wAQwogk4gAU


Jianqiang Li Ph.D.

Founder, CSO


Over 20 years experience in immunology and cell therapy, published 13 papers in Nature Medicine, Blood, Journal of Immunology, etc., cumulative impact index over 60. Invited speaker at ASH, ASBMT, ICBS, ECI and Gamma-Delta T Cell International Conference


Independently set up an efficient CAR-T production system, achieved major breakthroughs in the development and clinical transformation of allogeneic CAR-γδ T cell therapy, and made important contributions to the antigen presentation and activation mechanism of Vγ9Vδ2 T cells. Successfully developed CAR-γδ T cell products based on γδ T cells, enriching Senlang's cell therapy pipeline




快乐飞艇综合走势图 快乐飞艇做任务靠谱吗 熊猫乐园快乐飞艇 华创投资快乐飞艇靠谱吗 快乐飞艇app首页 快乐飞艇计划 快乐飞艇app下载 快乐飞艇官网 快乐飞艇技巧 快乐飞艇开奖